Parallel ultra high pressure liquid chromatography-mass spectrometry for the quantification of HIV protease inhibitors using dried spot sample collection format

被引:16
作者
Watanabe, Kyoko [1 ,2 ]
Varesio, Emmanuel [1 ]
Hopfgartner, Gerard [1 ]
机构
[1] Univ Geneva, Univ Lausanne, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland
[2] Shimadzu Co Ltd, Global Applicat Dev Ctr, Kyoto, Japan
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2014年 / 965卷
关键词
Quantification; Plasma; Blood; DBS; LC-MS; Protease inhibitors; HUMAN PLASMA; ANTIRETROVIRAL DRUGS; HUMANS; DISPOSITION; RITONAVIR; DARUNAVIR; MS; PHARMACOKINETICS; QUANTITATION; METABOLISM;
D O I
10.1016/j.jchromb.2014.05.008
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An assay was developed and validated for the quantification of eight protease inhibitors (indinavir (IDV), ritonavir (RTV), lopinavir (LPV), saquinavir (SQV), amprenavir (APV), nelfinavir (NFV), atazanavir (AZV) and darunavir (DRV)) in dried plasma spots using parallel ultra-high performance liquid chromatography and mass spectrometry detection in the multiple reaction monitoring mode. For each analyte an isotopically labeled internal standard was used and the assay based on liquid-solid extraction the area response ratio (analyte/IS) was found to be linear; from 0.025 mu g/ml to 20 mu g/ml for IDV, SQV, DRV, AZV, LPV, from 0.025 mu g/ml to 10 mu g/ml for NFV, APV and from 0.025 mu g/ml to 5 mu g/ml for RTV using 15 mu l of plasma spotted on filter paper placed in a sample tube. The total analysis time was of 4 min and inter-assay accuracies and precisions were in the range of 87.7-109% and 2.5-11.8%, respectively. On dried plasma spots all analytes were found to be stable for at least 7 days. Practicability of the assay to blood was also demonstrated. The sample drying process could be reduced to 5 min using a commercial microwave system without any analyte degradation. Together with quantification, confirmatory analysis was performed on representative clinical samples. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:244 / 253
页数:10
相关论文
共 30 条
  • [1] Balani SK, 1996, DRUG METAB DISPOS, V24, P1389
  • [2] Blessborn D, 2013, BIOANALYSIS, V5, P31, DOI [10.4155/BIO.12.294, 10.4155/bio.12.294]
  • [3] Bruderer T, 2012, BIOANALYSIS, V4, P1907, DOI [10.4155/bio.12.158, 10.4155/BIO.12.158]
  • [4] Pharmacology and clinical experience with amprenavir
    Conway, B
    Shafran, SD
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (02) : 371 - 382
  • [5] Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
    Crommentuyn, KML
    Rosing, H
    Hillebrand, MJX
    Huitema, ADR
    Beijnen, JH
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 804 (02): : 359 - 367
  • [6] D'Arienzo CJ, 2010, BIOANALYSIS, V2, P1415, DOI [10.4155/bio.10.94, 10.4155/BIO.10.94]
  • [7] HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients
    D'Avolio, Antonio
    Siccardi, Marco
    Sciandra, Mauro
    Lorena, Baietto
    Bonora, Stefano
    Trentini, Laura
    Di Perri, Giovanni
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 859 (02): : 234 - 240
  • [8] Simultaneous Quantitation of HIV-Protease Inhibitors Ritonavir, Lopinavir and Indinavir in Human Plasma by UPLC-ESI-MS-MS
    Das Mishra, Tulsi
    Kurani, Hemal
    Singhal, Puran
    Shrivastav, Pranav S.
    [J]. JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2012, 50 (07) : 625 - 635
  • [9] Denissen JF, 1997, DRUG METAB DISPOS, V25, P489
  • [10] Oral contraception does not alter single dose saquinavir pharmacokinetics in women
    Fröhlich, M
    Burhenne, J
    Martin-Facklam, M
    Weiss, J
    von Wolff, M
    Strowitzki, T
    Walter-Sack, I
    Haefeli, WE
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) : 244 - 252